The Form 4 filing, an SEC report of insider stock activity, was filed on November 18, 2026. The three sales took place on November 16, 2026, two days before the filing date.
Gil M. Labrucherie, Septerna's chief financial officer, reported the activity in one filing. Septerna (SEPN) is listed in the healthcare sector and biotechnology industry.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-16 |
| Date of Latest Transaction | 2026-11-16 |
| Buy/Sell | sell |
| Transaction Count | 3 |
| Shares Transacted | 20,000 |
| Price | $41.62 |
| Total Transaction Value | $832,359.19 |
| Insider | |
| Ticker Symbol | SEPN |
| Company | Septerna, Inc. |
| Insider Name | Labrucherie Gil M |
| Insider Title | Chief Financial Officer |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 20,000 |
| Position Size Change | 50.00% |
| Filing | |
| Filing Date | 2026-11-18 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were share sales, reported under transaction code S. The filing lists three sale transactions by Gil M. Labrucherie.
What was the average price of the transaction?
The average sale price was $41.62 per share across the three transactions. Individual sale prices are not included in the available details.
How did this transaction affect the insider's holdings?
The sales reduced the reported holdings by 20,000 shares and left 20,000 shares owned afterward. That was 50.00%, or half, of the shares held before the sales, based on the reported balance.
What's the total transaction value?
The total value was $832,359.19 for the three sales combined. This amount covers all 20,000 shares sold on November 16, 2026.
Are there any special circumstances around this transaction?
The transaction information includes a Rule 10b5-1 plan reference. These plans set trading instructions in advance. Footnote text is not available, so it is unclear which of the three sales the reference covers. The plan's adoption date, trading schedule, and other terms are also unknown.
For research purposes only; not investment advice.